The bottom line: Many small biopharmas with little to no revenue (yet) are working on the frontlines of the pandemic. They need every dollar they can get to fund R&D on vaccines and treatments for COVID-19—not to mention cures for other deadly diseases and solutions to heal, feed, and fuel the world.
BIO's advocacy work is always shaped by our members. And we need everyone at the table. If you are a BIO member, consider joining a policy committee. If your company is not yet a member, learn more and consider joining today.
More Health Care News:
ACS CAN: Efforts to reduce drug prices must balance affordability with access to innovation and safety
“While we acknowledge the administration’s attempt to further examine new ways to tackle prescription drug costs, this must be done in a manner which balances affordability with access to innovation and maintaining safety,” said the American Cancer Society’s Cancer Action Network (CAN).
Biopharma Dive: BioNTech, Pfizer pick a surprise coronavirus vaccine, follow Moderna into late-stage test
“The two companies claim the version they chose for Phase 3 study was better tolerated than the one they advanced first, and potentially more effective in protecting older people at higher risk of COVID-19.”
The New York Times: Long-sought blood test for Alzheimer’s in reach
“A newly developed blood test for Alzheimer’s has diagnosed the disease as accurately as methods that are far more expensive or invasive, scientists reported on Tuesday, a significant step toward a longtime goal for patients, doctors, and dementia researchers. The test has the potential to make diagnosis simpler, more affordable, and widely available.”
Agriculture and Environment News:
CleanTechnica: Seaweed to the rescue, from renewable energy to COVID-19 treatment
“If…COVID-19 helps stimulate commercial seaweed farming beyond its current scale, the implications for biofuel could be significant.”